Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
